Programmed Cell Death Protein 10 (PDCD10) Regulates Vesicle Trafficking and Contributes to the Progression of Clear Cell Renal Cell Carcinoma

ABSTRACT Vesicle trafficking is an essential cellular process that plays an important role in tumour progression. Here, we performed a comprehensive transcriptomic and proteomic analysis on 50 clear cell renal cell carcinoma (ccRCC) tumour samples, and the data systematically depicted the alteration...

Full description

Saved in:
Bibliographic Details
Main Authors: Rui Wang, Tianyu Lin, Yi Liu, Hao Wang, Xinyu Liu, Yihan Dong, Jiaxin Li, Huamao Jiang, Ruibing Chen, Yong Wang, Dan Yue
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Journal of Extracellular Vesicles
Subjects:
Online Access:https://doi.org/10.1002/jev2.70108
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Vesicle trafficking is an essential cellular process that plays an important role in tumour progression. Here, we performed a comprehensive transcriptomic and proteomic analysis on 50 clear cell renal cell carcinoma (ccRCC) tumour samples, and the data systematically depicted the alterations in the molecular landscape. Intriguingly, our investigation uncovered profound dysregulation of the vesicle trafficking process. Particularly, PDCD10 was overexpressed in ccRCC, and functional assays showed that PDCD10 promoted cell proliferation, migration and invasion in vitro and enhanced tumour growth in vivo. Additionally, we identified PDCD10 as a critical regulator of endocytosis and exosome secretion. Proteomic analysis of extracellular vesicles (EVs) suggested that PDCD10 overexpression altered the cargo content in EVs and elevated the abundances of cell adhesion and extracellular matrix molecules. Furthermore, Erlotinib treatment impaired PDCD10‐induced endocytosis and suppressed cell proliferation and invasion. Collectively, our findings underscore the significance of PDCD10 as a regulator of vesicle trafficking in ccRCC and a potential target for developing novel anticancer therapeutics.
ISSN:2001-3078